Navigation Links
Myriad Genetics Presents Tumor Origin Technology at AACR

that is not present in the unaffected specimen. If one of the tumors has many more additional changes than the other, it may be considered the secondary, or metastatic tumor. In our preliminary data set, copy number conclusions were subsequently confirmed by re-sequencing the PTEN tumor suppressor gene for mutations.

"We are excited about the potential of our copy number analysis technology to differentiate cancers of different types," said Jerry Lanchbury, Ph.D., Executive Vice President of Research for Myriad Genetics, Inc. "We anticipate further development of the technology for possible commercial introduction in the future."

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those related to the potential for copy number analysis to be used to determine the original location of a metastatic tumor or to prove helpful in determining whether any two tumors are related; and the further development of the copy number technology for possible commercial introduction in the future. These risks and uncertainties include, but are not limited to, our inability to further identify, develop and achieve commercial success for new products and technologies; our ability to discover drugs that are safer and more efficacious than our competitors; our ability to develop molecular diagnostic products that help assess which patients are subject to greater risk of developing diseases and who would therefore benefit from new preventive therapies; the possibility of
'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Tumor Origin Technology AACR
(Date:3/17/2010)... , Chief Financial Officer, will be presenting at the Barclays Capital Global Healthcare Conference on Wednesday, March 24 at 8:30 am Eastern Time .  The ... ... ... ...
(Date:3/17/2010)... On March 17, 2010 the FDA gave ... Kind" prosthetic hearing restoration device. The approval follows a December ... advisory panel in favor of approving the Esteem® for moderate to ... noting that they believe the Esteem® "represents a breakthrough technology." , ...
(Date:3/17/2010)... 17 Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam ... ... ... ...
Breaking Medicine Technology:DURECT to Present at the Barclays Capital Global Healthcare Conference 2DURECT to Present at the Barclays Capital Global Healthcare Conference 3FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device 2Actavis Receives Approval of Alprazolam ODT in the U.S. 2Actavis Receives Approval of Alprazolam ODT in the U.S. 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 1Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 2Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 4Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 5Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 1Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 4Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3
... TURKU, Finland, May 28 BioCis Pharma Ltd., ... Turku,Finland, has started Phase I clinical testing of ... urinary bladder cancer.,ProtoCure is based on a new ... which effectively prevents cancer growth and proliferation,locally. , ...
... show superiority of endoscopic ablation therapy using the ... multicenter, sham controlled trialSUNNYVALE, Calif., May 27 ... the New England Journal of Medicine ... (BARRX Medical, Inc.) is highly effective for complete ...
Other Medicine Technology:BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug 2Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development 2Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development 3
(Date:3/18/2010)... take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide for the 15th annual Kick Butts Day.  More ... ... , ... ...
(Date:3/18/2010)... work/life solutions, today announced that it has been named to the Center for Companies That Care Honor Roll for the third straight year. , ... , ... ... ...
(Date:3/18/2010)... ... ... WASHINGTON , March 18 The following is a statement by Cheryl G. Healton , ... , , ...
(Date:3/18/2010)... Ill. March 18, 2010 Two new studies ... Third Eye Retroscope (TER), a retrograde viewing device, during ... standard colonoscopy detected 13.2 percent more polyps than colonoscopy ... second study examined endoscopist experience using TER and its ...
(Date:3/18/2010)... are only beginning to understand how individual variation in gene ... susceptibility to certain diseases. Now, an ambitious survey of the ... regulators called transcription factors to DNA that affect how genes ... is published in the March 18, 2010, issue of ...
Breaking Medicine News(10 mins):Health News:Nevada Kids 'Kick Butts' on March 24 2Health News:Nevada Kids 'Kick Butts' on March 24 3Health News:Nevada Kids 'Kick Butts' on March 24 4Health News:Bright Horizons Honored as 'Company that Cares' for Third Straight Year 2Health News:Bright Horizons Honored as 'Company that Cares' for Third Straight Year 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Studies examine Third Eye Retroscope during colonoscopy 2Health News:Studies examine Third Eye Retroscope during colonoscopy 3Health News:Studies examine Third Eye Retroscope during colonoscopy 4Health News:Studies examine Third Eye Retroscope during colonoscopy 5Health News:Transcription factors may dictate differences between individuals 2Health News:Transcription factors may dictate differences between individuals 3Health News:Transcription factors may dictate differences between individuals 4
... now faces the risk of losing his leg after he caught ... infected when he was being treated, but nurses told him it ... only to learn that gangrene had set in. ,"I've ... feel really let down by the hospital and the doctors. You're ...
... by Dr. Edward A. Hirschowitz and Dr. Li Zhong could help ... high risk for developing the disease. // Lung cancers are ... the world mainly because of the disease being diagnosed at a ... 49% higher than the national rate. However, the blood test ...
... of lung and brain damage in some very low birth ... years to assess the long-term, protective benefits of the treatment ... John Kinsella, MD, a neonatologist with the Pediatric Heart Lung ... of pediatrics at the University of Colorado at Denver and ...
... led the research at the London School of Economics said ... daughter than a son as their first child. ... benefit from attractiveness more than sons. He said that this ... years. Men’s reproductive success depends largely on status and women’s ...
... failure disrupted the functioning of 80 NHS Hospital Trusts ... ,NHS Connecting for Health, which is in charge of ... North-West England and the West Midlands were interrupted due ... administration systems inaccessible. A manual log will be maintained ...
... Winnipeg, Manitoba, Canada is nominated as a reference laboratory ... spongiform encephalopathy (BSE), or mad-cow disease and bird flu. ... and technical training for scientific personnel around the world, ... both the diseases. Canadian Agriculture Minister Chuck Strahl was ...
Other Medicine News:Health News:New Blood Test For Early Detection Of Lung Cancer 2Health News:Early Nitric Oxide Treatment Can Help Low Birth Weight Preemies 2Health News:Early Nitric Oxide Treatment Can Help Low Birth Weight Preemies 3
Scoville Hemilaminectomy Retractor...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
... Bone Graft represents an rhBMP-2 (recombinant human ... a bovine-derived absorbable collagen sponge (ACS) carrier. ... device is indicated for spinal fusion procedures ... disease (DDD) at one level from L4-S1, ...
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: